Nir Uriel, MD MSc
@NirUrielMD
Followers
6K
Following
1K
Media
85
Statuses
569
Cardiologist • Director of Advanced Heart Failure and Transplant @nyphospital • Professor of Medicine @ColumbiaMed @WeillCornell
New York, NY
Joined January 2018
Benefits of ICDs & CRT-Ds⚡️ in HM3 LVAD pts is uncertain. This analysis of the MOMENTUM-3 trial showed that the presence of these devices was not associated with ⬆️survival, quality of life, or functional capacity in HM3 LVAD pts. 🔗 https://t.co/16LwyClnph
2
10
24
In this post-hoc analysis of the ARIES trial in patients with Diabetes/Obesity/A-Fib and a HM3 LVAD, withdrawal of aspirin was not associated with increased risk of hemocompatibility related AEs Link to our open access report now in @JCardFail 📋 https://t.co/ySwijBY6Dn
0
2
15
Our latest analysis from the SHORE registry now in @TheJHLT comprised of nearly 2000 pts with heart transplant Read here about the risk of dual + GEP/dd-cfDNA https://t.co/p1sXtXIPBw
@JeffTeuteberg @KiranKhush1 @CareDx
2
8
34
Excited to share our review of Novel Artificial Intelligence Applications in Heart Transplant, published now in @CJCJournals: https://t.co/MPbIb84j9d In this article, we discuss published studies and future prospects for AI in HT, 1/x >
1
4
22
🔥 Big news from CADENCE — positive topline results hitting all the right notes. Targeting PH in heart failure may finally be finding its rhythm. 🫀🎵 @mardigomberg @jeanlucvachiery
https://t.co/mDNLNlFl2S
businesswire.com
Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With CpcPH due to HFpEF
4
18
53
Great day of teaching and learning at the Chicago Hemodynamics Forum Fellows Day — history, hemodynamics, and heart failure all in one place. 📚💡 A selfie for the win! 🤳 #CardioTwitter #Hemodynamics @ChiHForum @MUSC_Cardiology
Panel discussion focusing on the current and future of heart failure care with @NirUrielMD @MarkBelkinMD @RyanTedfordMD Dr. Dan Burkhoff, Dr. Ted Feldman, @MosiB, and @ritabirchard #ChiHemo2025
2
13
67
New study from @ColumbiaMed on Belatacept in #HeartTx: improved renal function, similar rejection-free survival compared to standard of care. A promising adjunct for high-risk patients. 🫀 @NirUrielMD 🔗:
0
10
21
What is the importantance of having both +dd-cf-DNA AND +GEP post heart transplant ? In this paper we observ a 6-fold increase risk of mortality + explore further the importance of positive biomarkers in post Transplant surveillance @CU_Cardiology
https://t.co/pjSVgJ1dCA
onlinelibrary.wiley.com
Introduction Donor-derived-cell-free-DNA (dd-cfDNA) and peripheral-gene-expression-profiling (pGEP) are tools for monitoring heart transplant (HT) recipients for rejection. We aimed to assess the...
2
3
16
Don’t miss the Main study prompting our editorial 👉 https://t.co/D5UuyMYtJT A pivotal look at how pre-LVAD MCS use influences outcomes and long-term success by Kanwar et al @PalakShahMD @JonGrinsteinMD @JHMontfort10 @NirUrielMD #JACCHF
0
2
10
Thrilled to collaborate with @shelleyhallmd on this editorial on Temporary #MCS before durable #LVAD @JACCJournals #JACCHF 👉 https://t.co/2Ir7rkDGCH 🎯 As our field embraces various #MCS strategies, the challenge is not just can we bridge; but should we, and for whom!!
3
13
54
What are the clinical implications of +ddcfDNA in HTx pts with negative EMB? We observed a significantly higher risk of adverse clinical events (mortality/graft dysfunction) in this specific cohort Now in @CircHF
https://t.co/4GkPShDIa0
5
10
43
Epic meal at Cocina de Autor & some *very* entertaining stories shared by @NirUrielMD, Manreet, Jacob Møeller, @JumeanMarwan @bobbi_hf & @hfdocbhimaraj at #CSLATAM2025. Nir with the best quote of the night: “Excuse me - does my dish have any hallucinogenic mushrooms?”
1
1
14
Another from #HFSA2025: this time looking at a new CCM-D device in patients with HFrEF. Will this be enough for CCM to gain traction in the HF world? @NirUrielMD @BurkhoffMd @SantosGallegoMD
https://t.co/xtt4p9cxVJ
tctmd.com
The Integra-D trial shows the device, which provides cardiac contractility modulation and defibrillation, also eases symptoms.
0
2
6
Great turn out for our #HFSA2025 industry innovation event! Attendees joined us to learn how the #CardioMEMS HF System and the #HeartMate3 LVAD are each advancing #HeartFailure management. 💙 We also heard powerful stories from patients whose lives have been changed by these
0
3
22
0
8
58
Excited for the 2025 Heart Failure Research Symposium! Looking forward to listen to the key note speaker and winner of the research competition by Dr. Martin Leon on the journey of structural heart! There is still time to join us this afternoon! Sign up below
3
4
22
Join us at HFRI Research Symposium! We’re already at 40 abstracts and counting!! Registration below!
3
7
42
“Out of Sequence Heart Transplants: Why, How Many, and to Whom” Our new analysis in @TheJHLT on the prevalence and factors associated with out of sequence heart allocation @ColumbiaCVRI
jhltonline.org
Heart transplantation (HT) is governed by the Organ Procurement and Transplantation Network, which commissions 56 organ procurement organizations (OPO) to perform allocation. Each allocation follows...
4
14
57
Our @CU_Cardiology experience with letermovir prophy for mod/high risk CMV post-OHT, a promising new therapy to avoid the typical leukopenia seen with valcyte Link to article now in @JCardFail
https://t.co/nb6YiKCV9o
onlinejcf.com
Cytomegalovirus (CMV) is a beta herpesvirus that is ubiquitous in the general population and usually results in an asymptomatic or self-limiting infection in the immunocompetent patient. However, in...
1
9
33